The Role of α-Interferon in Essential Thrombocythaemia, Polycythaemia Vera and Myelofibrosis with Myeloid Metaplasia (MMM): A Concise Update

References

• Dameshek W. Some speculation on the myeloproliferative syndroms (editorial). Blood. 1951; 6: 732
   Google Scholar
• Fialkow P.J. Clonal ad stem cell origin of blood cell neoplasm. Contemporary hematology oncology, J. Lobue, A.S. Gordon, S. Silber, et al. Plenum., New York 1080; Vol 1: 1
   Google Scholar
• Testa J., Karnofsky J.D., Rowley J.R., et al. Karyotipic patterns and their clinical significance in polycythemia vera. Am. J. Hematol. 1981; 11: 29
   PubMed Web of Science ®Google Scholar
• Berger R., Bernheim A., Le Coniat M., et al. Chromosome studies in polycythemia Vera patients. Cancer Genet. Cytogenet. 1984; 12: 217
   PubMed Web of Science ®Google Scholar
• Raskind W.H., Fialkow P.J. The use of cell markers in the study of human hematopoietic neoplasia. Advances in cancer research, G. Klein, S. Weinhouse. Academic Press., London 1987; 127–167
   Google Scholar
• Ferraris A.M., Giuntini P., Galiano S., Gaetani G.F. 2-deoxy-glucose-6-phosphaie utilization in the study of glucose-6-phosphate dehydrogenase mosaicism. Hum. Genet. 1981; 33: 307–313
   Web of Science ®Google Scholar
• Mc Taylor K.D., Shetta M., Talpaz M., et al. Myeloproliferative Disorders: Usefulness of X-linked Probes in Diagnosis. Leukemia. 1989; 3: 419–422
   PubMed Web of Science ®Google Scholar
• Thomas E.D., Clift R.A. Indications for marrow transplantation in chronic myelogenous leukemia. Blood 1989; 73: 861–864
   PubMed Web of Science ®Google Scholar
• McTalpaz M., Credie K.B., Mavligit G.M., Guttermann J.U. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983; 62: 689–692
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H., McCredie K., et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myclogenous leukemia. N. Engl. J. Med. 1986; 314: 1065–1069
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kaniarjian H., Kurzrock R., Trujillo J.M., Guttermann J.U. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann. Intern. Med. 1991; 114: 532–538
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on chronic myeloid leukemia., Interferon alpha-2a as comparered with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 1994; 320: 820–825
   Google Scholar
• Tobelem G. Essential thrombocythaemia. Baillierre's Clinical Haematol. 1989; 2: 3
   Google Scholar
• Geller S.A., Shapiro E. Acute leukemia as a natural sequel to primary thrombocythemia. Am. J. Clin. Pathol. 1982; 77: 353–356
   PubMed Web of Science ®Google Scholar
• Donovan P.B., Kaplan M.E., Goldberg J.D., et al. Treatment of polycythemia Vera with hydroxyurea. Am. J. Hematol. 1984; 17: 329
   PubMed Web of Science ®Google Scholar
• Reiffers J., Dachary D., David B., et al. Megakaryoblastic transformation of primary thrombocythemia. Acta Haemat. 1985; 73: 228–231
   PubMed Web of Science ®Google Scholar
• Silverstein M.N., Petitt R.M., Solberg L.A., et al. Anagrelide: a new drug for treating thrombocytosis. N. Eng. J. Med. 1988; 318: 1292–1294
   PubMed Web of Science ®Google Scholar
• Vinti H., Taillan P., Pesce A., et al. Megakaryoblastic transformation of essential thrombocythemia, hypercalcemia and lytic bone lesions. Acta Haemat. 1990; 83: 53
   PubMed Web of Science ®Google Scholar
• Nand S., Messmore Gross H., Fisher S., et al. Leukemic transformation in polycythemia Vera: analysis of risk factors. Am. J. Hamatol. 1990; 34: 32–36
   PubMed Web of Science ®Google Scholar
• Van den Anker-Lugtenburg P.J., Sizoo W. Myelodysplastic syndromes and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea. Am. J. Hematol. 1990; 33: 152
   PubMed Web of Science ®Google Scholar
• Schimke R.T., Sherwood S.W., Hill A.B., Johnston R.N. Overreplication and recombination of DN4 in higher cukaryotes: potential consequences and biological implications. Proc. Natl. Acad. Sci. USA 1986; 83: 2157–2161
   PubMed Web of Science ®Google Scholar
• Anagrelide Study Group., Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am. J. Med. 1992; 92: 69–76
   PubMed Web of Science ®Google Scholar
• Solberg L.A., Oles K.J., Tarach J., et al. The effects of anagrelide on human megakaryocytopoiesis. Blood. 1989; 74: 20, suppl 1.
   Google Scholar
• Lazzarino M., Vitale A., Morra E., et al. Therapy of essential thrombocythemia with alpha-interferon: results and prospects. Eur. J. Haematol 1990; 45: 15–21, suppl 52.
   PubMed Web of Science ®Google Scholar
• Sacchi S., Tabilio A., Leoni P., et al. Interferon alpha-2b in the long-term treatment of essential thrombocythemia. Ann. Hematol. 1991; 63: 206–309
   PubMed Web of Science ®Google Scholar
• Giles F. Maintenance therapy in myeloproliferative disorders: the current options. Hr. J. Haematol. 1991; 79: 92–95
   PubMed Web of Science ®Google Scholar
• Cervantes F., Salgado C., Feliu E., et al. Interferon alpha-. 2b for essential thrombocythemia: results in 13 previously untreated patients. Leukemia and Lymphoma. 1991; 4: 351–354
   PubMed Web of Science ®Google Scholar
• Giralt M., Rubio D., Cortes M.T., et al. Alpha interferon in the management of essential thrombocythaemia. Eur. J. Cancer. 1991; 27: 72–74, suppl 4
   PubMed Web of Science ®Google Scholar
• Gisslinger H., Chott A., Scheithauer W., et al. Interferon in essential thrombocythaemia. Br. J. Haematol. 1991; 79: 42–47, suppl 1
   PubMed Web of Science ®Google Scholar
• Kasparu H., Bernhart M., Krieger O., Luiz D. Remission may continue after termination of rlFNα-Lb treatment for essential thrombocythemia. Eur. J. Hamatol. 1992; 48: 33–36
   PubMed Web of Science ®Google Scholar
• Gugliotta L., Catani L., Vianelli N., et al. Rescue of anti-interferon antibody positive essential thrombocythaemia patients. Haematologica 1901; 76: 50, suppl 4
   Google Scholar
• Freund M. Interferons in hematology. Proceedings of the Educational Programme of the XIIth Meeting of the International Society of Haematology (European and African division). 1993. Vienna August 28-September 3, 1993; 1993, Schattaner, Struttgard. New York
   Google Scholar
• Middelhoff und G., Boll L. A long-term clinical trial of interferon-alpha therapy in essential thrombocythemia. Ann. Hematol. 1992; 64: 207–209
   PubMed Web of Science ®Google Scholar
• Sacchi S., Tabilio A., Leoni P., et al. Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term α-IFN treatment. Ann. Hematol. 1993; 66: 245–246
   PubMed Web of Science ®Google Scholar
• Perkins J., Israels M.C.G., Wilkinson I.F. Polycythaemia vera: Clinical studies on a series of 127 patients managed without radiation therapy. J. Med. 1964; 33: 499–518
   Google Scholar
• European Organization for Research on Treatment of Cancer “Leukemia and Hematosarcoma” Cooperative Group., Treatment of polycythemia vera by radioactive phosphorus or busulfan: a randomized trial. Sr. J. Cancer 1981; 44: 74–80
   Google Scholar
• Wasserman L.R., Balcerzak S.P., Berk P.D., et al. Influence of therapy on causes of death in polycythemia Vera. Trans. Assoc. Am. Physicians 1981; 94: 30–38
   PubMedGoogle Scholar
• Ellis J.T., Peterson P., Geller S.A., et al. Studies of the bone marrow in polycythemia Vera and the evolution of myelofibrosis and second hematologic malignancies. Semin. Hemataol. 1986; 23: 144–155
   PubMed Web of Science ®Google Scholar
• Silverstein M.N. Postpolycythemia myeloid metaplasia. Arc. Intern. Med. 1974; 134: 113–115
   PubMed Web of Science ®Google Scholar
• Silverstein M.N. The evolution into and the treatment of late stage Polycythemia Vera. Semin. Hematol. 1986; 13: 79
   Google Scholar
• Modan B., Lilienfeld A.M. Polycythemia Vera and leukemia—the role of radiation treatment: A study of 1222 patients. Medicine 1965; 44: 305–344
   PubMed Web of Science ®Google Scholar
• Berk P.D., Goldberg J.D., Silvertein M.N., et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N. Dial. J. bled. 1981; 304: 141–447
   PubMedGoogle Scholar
• Landaw S.A. Acute leukemia in polycythemia Vera. Semin. Hematol. 1986; 23.: 156–165
   PubMed Web of Science ®Google Scholar
• Vaquez H. Sur une forme speciale de cyanose s'accompanant d'hyperglobulie excessive et persistente. Compt. Rend. Soc. de biol. 1892; 13: 143–158
   Google Scholar
• Chievits E., Thiede T. Complications and causes of death in polycythemia vera. Acta. Med. Scand. 1962; 172: 513–523
   PubMed Web of Science ®Google Scholar
• Gardner F.H. Treatement of polyeythemia vera. Semin. Hematol. 1966; 3: 220
   Google Scholar
• Logue G.L., Gutterman J.O., McGinn T.G., et al. Melphalan therapy of polyeythemia vera. Blood. 1980; 36: 70
   Google Scholar
• Sharon R., Tatarsky I., Ben-Arich Y. Treatment of polycythemia Vera with hydroxyurea. Cancer. 1985; 57: 718
   Web of Science ®Google Scholar
• Kaplan M.E., Mack K., Goldberg J.D., et al. Long-term management of polycythemia Vera with hydroxyurea: a progress report. Semin. Hematol. 1986; 23: 167
   PubMed Web of Science ®Google Scholar
• Berk P.D., Goldberg J.D., Balcerzak S.P., et al. Non hematologic malignancies in patients receiving myelosuppressive treatment for polycythemia vera. Clin. Res. 1982; 30(2)558A
   Google Scholar
• Tartaglia A.P., Goldberg J.D., Silverstein M.N., et al. Aspirin and persantine do not prevent thrombotic complications in patients with polycythemia Vera treated with phlebotomy. Blood 1981; 58: 240A
   Google Scholar
• Silver R.T. Recombinant interferon-alpha for treatment of polycythemia vera. Lancer 1988; ii: 403
   Google Scholar
• Cacciola E., Giustolisi R., Guglielmo P., et al. Recombinant interferon a in the treatment of Polycythemia Vera. Blood 1991; 77: 2790
   PubMed Web of Science ®Google Scholar
• Turri D., Mitra Di M.E., Trapani R., et al. Alpha-interferon in polycythemia Vera and essential thrombocythemia. Hematologica 1991; 76: 75–76
   PubMed Web of Science ®Google Scholar
• Papineschi F., Bucalossi A., Capochiani E., et al. Recombinant interferon-alpha 2a for the treatment of Polycythemia Vera: Fourier trasform infrared microspectoscopy (FT-IR) study. 24th Congress of the International Society of Hematology. LondonUK August, 1992; 23–27; 1992, 1345A
   Google Scholar
• Silver R.T. Interferon-α2b A new treatment for Polycythemia Vera. Ann. Intern. Med. 1993; 119(11)1091
   PubMed Web of Science ®Google Scholar
• Cimino R., Rametta V., Matera C., et al. Recombinant interferon α-2b in the treatment of polycythemia vera. Am. J. Hematol. 1993; 44: 155–157
   PubMed Web of Science ®Google Scholar
• Ariad S., Bezwoda W.R. α-IFN for polycythemia vera. Blood. 1991; 77: 670
   PubMed Web of Science ®Google Scholar
• Finelli C., Gugliotta L., Gamberi B., et al. Relief of intractable pruritus in polycythemia vera with recombinant interferon alpha. Am. J. Hematol. 1993; 43: 316–318
   PubMed Web of Science ®Google Scholar
• Sacchi S., Leoni P., Liberati M., et al. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Ann. Hematol. 1994; 68: 247–250
   PubMed Web of Science ®Google Scholar
• Hino M., Futami E., Okuno S., et al. Possible selective effects of interferon α-2b on a malignant clone in a case of polycythemia Vera. Ann, Hematol. 1993; 66: 161–162
   PubMed Web of Science ®Google Scholar
• Messora C., Bensi L., Vecchi A., et al. Cytogenetic conversion in a case of polycythemia vera treated with interferon-alpha. Br. J. Haematol. 1994; 86: 402–404
   PubMed Web of Science ®Google Scholar
• Bajlin T.P., Price S.M., Boughton B.J. A reversible defect of platelet PDgF content in myeloproliferative disorders. Br. J. Haematol. 1988; 69: 483–486
   PubMed Web of Science ®Google Scholar
• Barosi G., Berzuini C., Liberato L.N., et al. A prognostic classification of myelofibrosis with myeloid metaplasia. Br. J. Haematol. 1988; 70: 397–401
   PubMed Web of Science ®Google Scholar
• Weinstein I.M. Idiopathic myelofibrosis: historical review, diagnostic and management. Blood review 1991; 5: 98–104
   PubMed Web of Science ®Google Scholar
• Barosi G. New trends in the treatment of myelofibrosis with myeloid metaplasia. Forum-trends in experimental and clinical medicine 1993; 3: 59–69
   Google Scholar
• Parmeggiani L., Ferrant A., Rodhain J., Michaux J.L., Sokal G. a-interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur. J. Haematol. 1987; 39: 228–232
   PubMed Web of Science ®Google Scholar
• Hasselbach H. Interferon in myelofibrosis. Lancer 1988; i: 355
   Google Scholar
• Seewann H.L., Gastl G., Lang A., et al. Interteron-alpha-2 in the treatment of idiopathic myelofibrosis. Blut 1988; 56: 161–163
   PubMedGoogle Scholar
• Turri D., Mitra Di M.E., Trapani R., Caiozzo A. Alpha interferon in primary myelofibrosis. Haematologica 1989; 74: 417–418
   PubMedGoogle Scholar
• Gisslinger H., Linkesh W., Fritz E., et al. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancer 1989; i: 634–639
   Google Scholar
• Barosi G., Liberato L.N., Costa A., et al. Induction and maintenance a-interferon therapy in myelofibrosis with myeloid metaplasia. Eur. J. Haematol. 1990; 45: 12–14, suppl. 52
   Web of Science ®Google Scholar
• McCarthy D., Clark J., Giles F. The treatment of myelofibrosis with a-interferon. Br. J. Haematol. 1991; 78: 590–591
   PubMed Web of Science ®Google Scholar
• Furesi Laghi L., Pasini F., Forconi S. Interferon a-2b in the treatment of myelofibrosis. Haematologica 1990; 75: 587–589
   Google Scholar
• Dalla K.P., Zeigler Z.R., Shadduck R.H. α-interferon in myelofibrosis: a case report. Br. J. Haematol. 1994; 86: 654–656
   PubMed Web of Science ®Google Scholar
• Kantarjian H.M., Deisseroth A., Kurthrock R., Estrov Z., Talpaz M. Chronic myelogenous leukemia: A consise up date. Blood. 1993; 82: 691–703
   PubMed Web of Science ®Google Scholar
• Akard L.P., Hoffman R., Elias L., Saiers J.H. Alpha-interferon and immune hemolytic anemia. Ann. Intern. Med. 1986; 105: 306
   PubMed Web of Science ®Google Scholar
• Abdi E.A., Venner P.M. Immune thrombocytopenia after a-interferon therapy in patients with cancer. J.A.M.A. 1986; 255: 1878–1879
   PubMed Web of Science ®Google Scholar
• Conlon K.C., Urba W.J., Smith J.W., II, et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer. 1990; 65: 2237–2241
   PubMed Web of Science ®Google Scholar
• Wandl Nagel-Hiemke U.B., May M.D., et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin. Immunol. Imrmmopurhol. 1991; 65: 70–74
   Web of Science ®Google Scholar
• Kurschel Metz- E., Kurschel U.M., Niederle N., Aulbert E. Investigations on the subclinical and clinical nephrotoxicity of interferon α-2b in patients with myeloproliferative syndromes. Renal Failure 1991; 13: 87–93
   PubMed Web of Science ®Google Scholar
• Gisslinger H., Gilly B., Woloszczuk W., et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. J. Exp. Immunol 1992; 90: 363–367
   PubMed Web of Science ®Google Scholar
• Sacchi S., Kantarjian H., Cohen P., Pierce S., Talpaz M. Immune-mediated and unusual complications during alpha-interferon therapy in chronic myelogenous leukemia, Submitted
   Google Scholar
• Guyer D.R., Tiedeman J., Yannuzzi L.A., et al. Interferon-associated retinopathy. Arch. Opthalmol. 1993; 111: 350–356
   PubMed Web of Science ®Google Scholar
• Sonnenblick M., Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest. 1991; 99: 557–561
   PubMed Web of Science ®Google Scholar
• Chott A., Gisslinger H., Thiele J., et al. Interferon alpha induced morphological changes of megakaryocytes: a histomorpho-metrical study on hone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br. J. Haematol. 1990; 74: 10–16
   PubMed Web of Science ®Google Scholar